



Prescient Therapeutics Company Profile

Overview

Prescient Therapeutics Limited (ASX:PTX) is a clinical stage oncology company developing treatments for cancers resistant to current front line chemotherapy treatments. The company's PTX-200 and PTX-100 compounds have been shown to block various known tumor survival pathways defined as Akt, Ral and Rho, in the development of solid tumors and various breast, ovarian and leukemia cancer cells.

The Company is currently conducting or has recently completed various clinical trials in breast cancer (Phase 1b trial recently completed); acute myeloid leukemia (Phase 1B/2 in progress) and ovarian cancer (Phase 1b trial in progress). The company is also planning a transformative trial in rare hematological cancers for PTX-100.

Speaker Profile

Steven Yatomi-Clarke, Chief Executive Officer and Managing Director



Mr Yatomi-Clarke was appointed as CEO and Managing Director of Prescient Therapeutics in February 2016, having previously been a Non-executive Director of the Company.

With a background in molecular biology, biochemistry, Mr Yatomi-Clarke has over 17 years' experience investment banking, healthcare and biotechnology, where he was consistently one of the most prolific and successful bankers, involved in primary and secondary offerings, corporate advisory and mergers and acquisitions assignments for pharmaceutical and medical device companies.

Mr Yatomi-Clarke has also been a collaborator on clinical trials conducted in Australia and the US in the field of cancer immunotherapy, with the rare distinction of readily bridging the divide between science and commerce.

Steven holds a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology, and a Bachelor of Commerce majoring in Economics, both from the University of Melbourne.